We only have this paper's title and publication details.
Read it at the sourceLOX may be a TEC marker and a possible therapeutic target for novel antiangiogenic therapy.
No takes yet. Share an insight, caveat, or question.
Osawa et al. (2013) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: